• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Incyte to Report Third Quarter Financial Results

    10/8/24 8:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $INCY alert in real time by email

    Incyte (NASDAQ:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 29, 2024.

    The schedule for the press release and conference call/webcast is as follows:

    • Q3 2024 Press Release:

    October 29, 2024 at 7:00 a.m. ET

    • Q3 2024 Conference Call:

    October 29, 2024 at 8:00 a.m. ET

    • Domestic Dial-In Number:

    877-407-3042

    • International Dial-In Number:

    201-389-0864

    • Conference ID Number:

    13749146

    If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13749146.

    The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.

    About Incyte

    A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

    For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241008194305/en/

    Get the next $INCY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INCY

    DatePrice TargetRatingAnalyst
    6/16/2025$107.00Hold → Buy
    Stifel
    3/18/2025Buy → Neutral
    Guggenheim
    3/18/2025Outperform → Mkt Perform
    William Blair
    12/17/2024$77.00Neutral
    UBS
    10/29/2024$68.00 → $90.00Neutral → Buy
    BofA Securities
    10/1/2024$84.00Outperform
    Wolfe Research
    9/18/2024$83.00 → $74.00Buy → Hold
    Truist
    7/2/2024$52.00 → $48.00Market Perform → Underperform
    BMO Capital Markets
    More analyst ratings

    $INCY
    SEC Filings

    See more
    • SEC Form S-8 filed by Incyte Corp.

      S-8 - INCYTE CORP (0000879169) (Filer)

      6/18/25 4:02:42 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form S-8 filed by Incyte Corp.

      S-8 - INCYTE CORP (0000879169) (Filer)

      6/18/25 4:01:35 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte Corp. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - INCYTE CORP (0000879169) (Filer)

      6/11/25 11:32:15 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care